Compare KB Financial Group, Inc. (KB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs TG Therapeutics Inc — how do they compare? KB Financial Group, Inc. trades at $118.91 (market cap $38.56B), while TG Therapeutics Inc trades at $54.22 (market cap $8.26B). The key difference: KB Financial Group, Inc. is far larger — about 4.7× TG Therapeutics Inc's market cap, and KB Financial Group, Inc. pays a 2.72% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| KB | TGTX | |
|---|---|---|
Market Cap | $38.56B | $8.26B |
Sector | Financials | Health |
52-Week High | $123.25 | $59.06 |
52-Week Low | $77.50 | $26.39 |
Dividend Yield | 2.72% | — |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $115.23, down 3.47% today, but maintains a bullish technical outlook with strong moving average signals. The company shows solid fundamental performance with a 27.82% net income margin and consistent earnings beats in recent quarters. Revenue growth has been steady, reaching $21.23T in 2025, while analyst sentiment is mixed with a 33.33% buy rating amid broader hold consensus. Recent news highlights diversification into non-banking segments, which now contribute 43% of earnings.
The stock presents a balanced outlook with upside from earnings growth and diversification efforts, but faces risks from volatile cash flows and macroeconomic pressures. Investors should weigh the attractive valuation metrics against execution risks in non-banking expansion. The current price near recent highs suggests cautious optimism is warranted.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.
The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
